[A16-46] Empagliflozin - Addendum to Commission A16-12
Last updated 01.09.2016
Project no.:
A16-46
Commission:
Commission awarded on 11.07.2016 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A16-12 | Empagliflozin - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-142 | Empagliflozin (type 2 diabetes mellitus in children and adolescents) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2016-09-01 A G-BA decision was published.